Supplementary Materials

Supplementary Material for:

Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients

Evangelos D. Michelakis,* Vikram Gurtu, Linda Webster, Gareth Barnes, Geoffrey Watson, Luke Howard, John Cupitt, Ian Paterson, Richard B. Thompson, Kelvin Chow, Declan P. O'Regan, Lan Zhao, John Wharton, David G. Kiely, Adam Kinnaird, Aristeidis E. Boukouris, Chris White, Jayan Nagendran, Darren H. Freed, Stephen J. Wort, J. Simon R. Gibbs, Martin R. Wilkins*

*Corresponding author. Email: em2{at}ualberta.ca (E.D.M.); m.wilkins{at}imperial.ac.uk (M.R.W.)

Published 25 October 2017, Sci. Transl. Med. 9, eaao4583 (2017)
DOI: 10.1126/scitranslmed.aao4583

This PDF file includes:

  • Fig. S1. Confocal immunohistochemistry of six PAH lungs and three non-PAH control lungs.
  • Fig. S2. Relationship between risk variants (SNP scores) and decrease in mPAP in patients treated with DCA.
  • Fig. S3. Relationship between the combined SNP score of both SIRT3 and UCP2 risk variants and the change in mPAP in patients treated with DCA.
  • Fig. S4. The effects of DCA on RV size and function.
  • Fig. S5. The effects of DCA on lung perfusion (MRI) and glucose uptake (18FDG-PET-CT).
  • Table S1. Gene variants score (SNPs) for DCA resistance.

[Download PDF]